Pillstats
OTC · Injection, Suspension · Subcutaneous

Human Insulin

Brands: Novolin 70/30 · Novolin N · Insulin Human

2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US5 NDCs
2 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)253182
US makers2 labelers
Packages9
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$1.50$3.01$4.51$6.01Dec 2025Apr 2026Jul 2026
$5.224
Latest avg · Jul 22, 2026
-0%
Since Dec 17, 2025
2
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

9.1K18K27K37K2025 Q12025 Q22025 Q32025 Q42026 Q1
23K
Rx · 2026 Q1
445K
Units dispensed
-27%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it2 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Novo Nordiskunknown8SUPPLYING
A-S Medication Solutionsunknown1SUPPLYING

Regulatory & supply events

No recalls, shortages, or registration changes on record for this drug concept.